Pilot study of hepatic arterial infusion chemotherapy followed by sorafenib for advanced hepatocellular carcinoma
Not Applicable
- Conditions
- advanced hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000009094
- Lead Sponsor
- Department of Gastroenterology and Metabolism,Hiroshima University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 55
Inclusion Criteria
Not provided
Exclusion Criteria
1) With other malignant disease. 2) A pregnant woman, or a woman suspected of pregnancy. 3) With severe infectious disease. 4) With history of severe allergy. 5) With severe renal function disease. 6) With severe allergy for 5FU or CDDP. 7) With severe bone marrow supression. 8) Esophageal and/or gastric varices which has high risk of bleeding and clinically significant gastro- intestinal bleeding. 9) Serious hypertension 10) Any condition that is unstable or could jeopardize the safety of the patient and its compliance in the study, in the investigator's judgment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The 1-year survival rate
- Secondary Outcome Measures
Name Time Method The 2-year survival rate Over all survival Respose rate of HAIC Survival rate according to HAIC response Time to progression of HAIC Response rate of sorafenib Survival rate according to sorafenib response Adverse events Liver function process